Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|December 17, 2024

Managing Clinical Technology Overload From a DCT Perspective

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights challenges with technology adoption including how sites may be asked to work with a variety of different providers.

In a recent video interview with Applied Clinical Trials, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discussed trends and challenges in decentralized clinical trials (DCTs) including misconceptions and the rapid adoption of DCT elements. Myles also highlighted DTRA's initiatives on site adoption, operational planning, and the integration of digital health technologies.

ACT: From a decentralized clinical trial (DCT) perspective, what are some best practices to ensure that stakeholders don’t feel overwhelmed by technology?

Myles: Now there are some other reasons people feel overwhelmed. Honestly, there are a lot of different providers out there, and especially as a site, you may be asked to work with many different providers, not even within the same study, but across the suite of studies you're doing. The technology burden feels higher when it feels like—I'm making this up now—the eConsent solution looks different when you work with vendor ‘X’ versus vendor ‘Y,’ but actually the core capabilities and the GCP (Good Clinical Practice) and data requirements are exactly the same. You still have to be trained on both to use them as a site member. Some sites have actually asked if there should be a consolidation, or a narrowing of the available options for these different methodologies. I'm strongly opposed to that, simply because that's not how this whole industry will work. However, I do think that over time, we're going to see some more common best practices and norms, even if we don't get to a state where you might have one training program that applies across every eConsent solution.

I think the other thing that's going to be really interesting here on tech adoption is that as the FDA inspectors and investigators who conduct the inspections go out and learn about these different platforms, they're going to become more familiar and comfortable with the technology too, and probably make recommendations. I'm not saying 483s, I'm saying they're more likely to be able to document anything we need to pay attention to in a guidance document, similar to the one they just released on electronic systems and signatures. Tech adoption is hard, especially when it feels like you're being asked to learn something new every week. I get that.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.